Research Summary

I take care of people with lymphoma and chronic lymphocytic leukemia. I believe in taking an individualized approach to each patient's care. By understanding their values and priorities, together we will arrive at the best treatment plan.

I graduated with honors from Emory University School of Medicine in Atlanta. I completed residency in Internal Medicine and fellowship in Hematology and Oncology at New York Presbyterian Hospital/Weill Cornell Medical Center in New York, where I also served as Chief Fellow. At UCSF I am fortunate to practice at a leading medical center which is at the forefront of cancer care.

Technologies for the diagnosis and treatment of lymphoma and CLL are rapidly evolving, and I will use the latest advancements in providing care for patients. We are also fortunate to have a strong team of specialty consultants, nurse practitioners, nurses, medical technicians, pharmacists, and administrative staff. It would be a privilege to care for you or your family member.

Education

2022 - Chief Fellow, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2022 - Fellowship, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2019 - Residency, Internal Medicine, New York-Presbyterian Hospital, Weill Cornell Medical Center
MD, 2016 - , Emory University School of Medicine
BA, 2009 - Neuroscience, Johns Hopkins University

Honors & Awards

  • Research Training Award for Fellows, American Society of Hematology, 2021-2022
  • Abstract Achievement Award, American Society of Hematology, 2021
  • Ann Hoyt Jolley Merit Scholarship, Emory University School of Medicine, 2015-2016

Selected Publications

  1. Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T. WBC Growth Factors: ASCO Guideline Update. J Clin Oncol. 2026 Mar 20; 44(9):812-824. View on PubMed
  2. Tolu SS, Gribbin C, Chen Z, Seshadri MR, Orlando E, Grenet J, Toor R, Sanjurjo A, Cherng HJ, Sawas A, Phillips A, Shore T, Martin P, Leonard JP, Inghirami G, van Besien K, Pro B, Amengual JE, Ruan J. Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leuk Lymphoma. 2025 Dec; 66(13):2437-2447. View on PubMed
  3. Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, Forman SJ, Nastoupil L, Budde LE. Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. Am J Hematol. 2025 Feb; 100(2):236-248. View on PubMed
  4. Barrios JP, Seshadri MR, Tison GH. Artificial Intelligence to Complement, Not Replace, Clinical Knowledge: Reading Between the Lines. JACC CardioOncol. 2024 Apr; 6(2):264-266. View on PubMed
  5. Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. Eur J Nucl Med Mol Imaging. 2023 09; 50(11):3349-3353. View on PubMed
  6. Laurence J, Nuovo G, Racine-Brzostek SE, Seshadri M, Elhadad S, Crowson AN, Mulvey JJ, Harp J, Ahamed J, Magro C. Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Am J Pathol. 2022 09; 192(9):1282-1294. View on PubMed
  7. Seshadri M, Crane GM, Gergis U. Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Hematol Oncol Stem Cell Ther. 2022 Mar 01; 15(1):68-73. View on PubMed
  8. Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk Lymphoma. 2022 04; 63(4):789-798. View on PubMed
  9. Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol. 2021 10 01; 96(10):E373-E376. View on PubMed
  10. Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020 10; 219:108555. View on PubMed
  11. Seshadri M, Qu CK. Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis. Curr Opin Hematol. 2016 07; 23(4):339-45. View on PubMed
  12. Attaluri A, Seshadri M, Mirpour S, Wabler M, Marinho T, Furqan M, Zhou H, De Paoli S, Gruettner C, Gilson W, DeWeese T, Garcia M, Ivkov R, Liapi E. Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. Int J Hyperthermia. 2016 08; 32(5):543-57. View on PubMed
  13. Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab. 2011 Mar 02; 13(3):308-19. View on PubMed

Go to UCSF Profiles, powered by CTSI